The Incidence of Type 2 Diabetes Mellitus and Weight Gain in People Living with HIV Receiving a Dolutegravir-Based Antiretroviral Therapy in Addis Ababa, Ethiopia: A Pilot Single-Arm Historical Cohort Study

Introduction: The development of antiretroviral therapy (ART) has immensely improved the quality of life of people living with HIV/AIDS. Despite such a change, concerns continue to persist regarding the safety of the latest drugs added to the regimens. This study aims to evaluate the incidence of type 2 diabetes mellitus (T2DM) and weight gain in individuals receiving antiretroviral therapy containing dolutegravir at a general hospital in Addis Ababa, Ethiopia. Methods: A retrospective cohort study was conducted at RDDMH from 1 February to 30 March 2022. The study included PLHIV who had dolutegravir substituted into their combined regimen in November 2019. Collected data underwent cleaning, entry, and analysis using Statistical Package for Social Sciences (SPSS) v. 26.0 and R programing. Descriptive statistics were employed for univariate and bivariate analysis. The Kaplan–Meier model in R was used to illustrate the hazard function. A significance level of p < 0.05 and a 95% confidence interval were employed for statistical reporting. Results: The study followed 185 PLHIV who were on ART who either substituted their previous regimens or initiated a new dolutegravir-based regimen for 12 months. Most were females (59.5%), aged over 38 years (57.5%), married (50.8%), and had lived with HIV for 7 or more years (51.9%). The incidence proportion of T2DM in this sample was 7.0% (95% CI: 3.8–10.3). The age category (X2(1, N = 185) = 12.29, p < 0.001) exhibited a statistically significant relationship with the incidence of T2DM. The cumulative rate of T2DM in the age group over 38 years was approximately 15.4%. The pairwise Wilcoxon signed rank test revealed statistically significant differences in BMI scores between time points. Conclusion: This study observed a noteworthy incidence of T2DM among PLHIV receiving a dolutegravir-based first-line ART. Healthcare providers should prioritize early follow-up and management options for PLHIV who are on dolutegravir-based ART regimens.